Novel agents for the treatment of adenocarcinoma of the pancreas.
about
Role of α-gal epitope/anti-Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancerTyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancerTailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands.Decreased RGS6 expression is associated with poor prognosis in pancreatic cancer patientsManagement of pancreatic cancer: current status and future directionsSlug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling.A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).Oncolytic virotherapy for pancreatic cancer.A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis.Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancerPotential targets for pancreatic cancer immunotherapeutics.Gemcitabine combined with gum mastic causes potent growth inhibition and apoptosis of pancreatic cancer cells.Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles.2-Triazenoazaindoles: α novel class of triazenes inducing transcriptional down-regulation of EGFR and HER-2 in human pancreatic cancer cells.The effect of JDP2 and ATF2 on the epithelial-mesenchymal transition of human pancreatic cancer cell lines.Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence.Development of detection method for novel fusion gene using GeneChip exon array.
P2860
Q27024368-6D94F58F-E19E-4A59-AC7B-1E4C22726657Q28740545-8378C2EE-2C03-4286-A0EB-B14E5EE2D254Q34005061-408675AA-F341-4349-B5A0-E1AC505A4BB5Q34029155-3665E10E-99E9-4D84-8DD8-F72E4D4F3E41Q34409883-A8FF59F9-C9D9-424E-A67C-8D2425071919Q35073648-7857F307-E3A1-48CE-99AD-4A36B26DE3C3Q35583855-EC1A9617-B5F0-49FA-A175-AF76CE720F11Q35590996-25526117-12B6-40AC-A275-2F64D657A3E7Q35791377-0B5022C2-3BCE-4891-8C53-76046EA1F492Q35876172-2EEA2E98-044B-4AFC-828D-35A7348D3BDCQ36896764-F3C05650-CB9C-4BE9-8829-9271C6852506Q37861220-829ADC89-C65E-48E3-B1A9-1A019E70852CQ39022283-96CAEF39-EE8A-4614-98B0-77BBE52F524CQ39186027-D1D63EAB-4349-4EED-BA58-866687B984B9Q39434302-5C805CB5-10C8-4257-A7FE-67D71F364AFAQ39438559-0F0AA87B-11EB-4EB0-99FF-01B895C2CBDBQ41130667-DAE47211-4952-4F46-953A-CACE3C767C0AQ41980965-38C07C30-CBE3-4BD0-8C83-33A50D96CF20
P2860
Novel agents for the treatment of adenocarcinoma of the pancreas.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel agents for the treatment of adenocarcinoma of the pancreas.
@en
Novel agents for the treatment of adenocarcinoma of the pancreas.
@nl
type
label
Novel agents for the treatment of adenocarcinoma of the pancreas.
@en
Novel agents for the treatment of adenocarcinoma of the pancreas.
@nl
prefLabel
Novel agents for the treatment of adenocarcinoma of the pancreas.
@en
Novel agents for the treatment of adenocarcinoma of the pancreas.
@nl
P2860
P356
P1476
Novel agents for the treatment of adenocarcinoma of the pancreas.
@en
P2093
A David McCollum
R Pamela Mackenzie
P2860
P304
P356
10.1586/ERA.09.109
P577
2009-10-01T00:00:00Z